Your browser doesn't support javascript.
loading
KRT17High/CXCL8+ tumor cells display both classical and basal features and regulate myeloid infiltration in the pancreatic cancer microenvironment.
Carpenter, Eileen S; Kadiyala, Padma; Elhossiny, Ahmed M; Kemp, Samantha B; Li, Jay; Steele, Nina G; Nicolle, Rémy; Nwosu, Zeribe C; Freeman, Julia; Dai, Henry; Paglia, Daniel; Du, Wenting; Donahue, Katelyn; Morales, Jacqueline; Medina-Cabrera, Paola I; Bonilla, Monica E; Harris, Lindsey; The, Stephanie; Gunchick, Valerie; Peterson, Nicole; Brown, Kristee; Mattea, Michael; Espinoza, Carlos E; McGue, Jake; Kabala, Sarah M; Baliira, Rachel K; Renollet, Nur M; Mooney, Ayden G; Liu, Jianhua; Bhalla, Sean; Farida, Jeremy P; Ko, Christopher; Machicado, Jorge D; Kwon, Richard S; Wamsteker, Erik-Jan; Schulman, Allison; Anderson, Michelle A; Law, Ryan; Prabhu, Anoop; Coulombe, Pierre A; Rao, Arvind; Frankel, Timothy L; Bednar, Filip; Shi, Jiaqi; Sahai, Vaibhav; Pasca di Magliano, Marina.
Afiliação
  • Carpenter ES; University of Michigan-Ann Arbor, Ann Arbor, MI, United States.
  • Kadiyala P; University of Michigan-Ann Arbor, Ann Arbor, MI, United States.
  • Elhossiny AM; University of Michigan-Ann Arbor, Ann Arbor, MI, United States.
  • Kemp SB; University of Pennsylvania, Philadelphia, PA, United States.
  • Li J; University of Michigan-Ann Arbor, Ann Arbor, MI, United States.
  • Steele NG; Henry Ford Hospital, Detroit, MI, United States.
  • Nicolle R; INSERM UMR1149, Paris, France.
  • Nwosu ZC; University of Michigan-Ann Arbor, Ann Arbor, United States.
  • Freeman J; University of Michigan-Ann Arbor, United States.
  • Dai H; University of Michigan-Ann Arbor, United States.
  • Paglia D; University of Michigan-Ann Arbor, United States.
  • Du W; University of Michigan Medical School, Ann Arbor, MI, United States.
  • Donahue K; University of Michigan-Ann Arbor, Ann Arbor, Michigan, United States.
  • Morales J; University of Michigan-Ann Arbor, Ann Arbor, United States.
  • Medina-Cabrera PI; University of Michigan-Ann Arbor, Ann Arbor, Michigan, United States.
  • Bonilla ME; University of Michigan-Ann Arbor, Ann Arbor, MI, United States.
  • Harris L; University of Michigan-Ann Arbor, Ann Arbor, MI, United States.
  • The S; University of Michigan-Ann Arbor, United States.
  • Gunchick V; University of Michigan-Ann Arbor, Ann Arbor, MI, United States.
  • Peterson N; University of Michigan-Ann Arbor, Ann Arbor, United States.
  • Brown K; University of Michigan Medical Schooligan, United States.
  • Mattea M; University of Michigan Medical School, Ann Arbor, MI, United States.
  • Espinoza CE; University of Michigan-Ann Arbor, Ann Arbor, United States.
  • McGue J; University of Michigan-Ann Arbor, Ann Arbor, MI, United States.
  • Kabala SM; University of Michigan-Ann Arbor, Ann Arbor, MI, United States.
  • Baliira RK; University of Michigan-Ann Arbor, Ann Arbor, MI, United States.
  • Renollet NM; University of Michigan-Ann Arbor, Ann Arbor, Michigan, United States.
  • Mooney AG; University of Michigan-Ann Arbor, Ann Arbor, MI, United States.
  • Liu J; University of Michigan-Ann Arbor, Ann Arbor, MI, United States.
  • Bhalla S; University of Michigan-Ann Arbor, Ann Arbor, MI, United States.
  • Farida JP; University of Michigan-Ann Arbor, Ann Arbor, MI, United States.
  • Ko C; University of Utah Hospital, Salt Lake City, Utah, United States.
  • Machicado JD; University of Michigan-Ann Arbor, Ann Arbor, MI, United States.
  • Kwon RS; University of Michigan-Ann Arbor, Ann Arbor, MI, United States.
  • Wamsteker EJ; University of Michigan-Ann Arbor, Ann Arbor, United States.
  • Schulman A; University of Michigan-Ann Arbor, Ann Arbor, MI, United States.
  • Anderson MA; Michigan Medicine, Ann Arbor, MI, United States.
  • Law R; University of Michigan-Ann Arbor, Ann Arbor, MI, United States.
  • Prabhu A; University of Michigan-Ann Arbor, Ann Arbor, MI, United States.
  • Coulombe PA; University of Michigan-Ann Arbor, Ann Arbor, MI, United States.
  • Rao A; University of Michigan-Ann Arbor, Ann Arbor, United States.
  • Frankel TL; University of Michigan Medical School, Ann Arbor, MI, United States.
  • Bednar F; University of Michigan-Ann Arbor, Ann Arbor, Michigan, United States.
  • Shi J; University of Michigan-Ann Arbor, Ann Arbor, MI, United States.
  • Sahai V; University of Michigan-Ann Arbor, Ann Arbor, MI, United States.
  • Pasca di Magliano M; University of Michigan-Ann Arbor, Ann Arbor, MI, United States.
Clin Cancer Res ; 2023 Oct 18.
Article em En | MEDLINE | ID: mdl-37851080
ABSTRACT

PURPOSE:

Pancreatic ductal adenocarcinoma (PDAC) is generally divided in two subtypes, classical and basal. Recently, single cell RNA sequencing has uncovered the co-existence of basal and classical cancer cells, as well as intermediary cancer cells, in individual tumors. The latter remains poorly understood; here, we sought to characterize them using a multimodal approach. EXPERIMENTAL

DESIGN:

We performed subtyping on a single cell RNA sequencing dataset containing 18 human PDAC samples to identify multiple intermediary subtypes. We generated patient-derived PDAC organoids for functional studies. We compared single cell profiling of matched blood and tumor samples to measure changes in the local and systemic immune microenvironment. We then leveraged longitudinally patient-matched blood to follow individual patients over the course of chemotherapy.

RESULTS:

We identified a cluster of KRT17-high intermediary cancer cells that uniquely express high levels of CXCL8 and other cytokines. The proportion of KRT17High/CXCL8+ cells in patient tumors correlated with intra-tumoral myeloid abundance, and, interestingly, high pro-tumor peripheral blood granulocytes, implicating local and systemic roles. Patient-derived organoids maintained KRT17High/CXCL8+cells and induced myeloid cell migration in an CXCL8-dependent manner. In our longitudinal studies, plasma CXCL8 decreased following chemotherapy in responsive patients, while CXCL8 persistence portended worse prognosis.

CONCLUSIONS:

Through single cell analysis of PDAC samples we identified KRT17High/CXCL8+ cancer cells as an intermediary subtype, marked by a unique cytokine profile and capable of influencing myeloid cells in the tumor microenvironment and systemically. The abundance of this cell population should be considered for patient stratification in precision immunotherapy.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos